---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-021461"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:45:07.771203+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx reaffirms FY2023 prelim revenue >$68-70M; updates 2024 revenue guidance to at least $100M

## Summary
- FY2023 preliminary revenue exceeds $68-70M range; adjusted EBITDA in $3-4M range, consistent with prior guidance.
- 2024 revenue guidance revised to at least $100M due to gross-to-net revenue recognition change for Medicx Health.
- 2024 adjusted EBITDA guidance unchanged at greater than $11M.
- FY2023 earnings call scheduled for March 28, 2024; year-end audit ongoing including Medicx Health and material weakness remediation.

## SEC filing metadata
- accession: 0001213900-24-021461
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390024021461/0001213900-24-021461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390024021461/ea0201581-8k_optimize.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-021461
- JSON: https://secwatch.observer/filing/0001213900-24-021461.json
- Plain text: https://secwatch.observer/filing/0001213900-24-021461.txt

## Key facts
- Earnings Releases
  OptimizeRx Corp reported FY2023 results: revenue $68-$70 million. Guidance reaffirmed.
  - Period: FY2023
  - Revenue: $68-$70 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: EBITDA guidance remains unchanged, at greater than $11 million for 2024. Based on its preliminary, unaudited review, OptimizeRx estimates FY2023 revenue to exceed the range of $68-$70 million and adjusted EBITDA to be in the range of $3-$4 million, which is consistent with the Company’s previously announced guidance. The estimated revenue and adjusted
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390024021461/0001213900-24-021461-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.